Clear-cell cancer of the ovary?is it chemosensitive?

Pather S, Selvan Pather, S Pather, M A Quinn, Michael Quinn
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2005 · vol. 15(3) , pp. 432–437 · doi:10.1111/j.1525-1438.2005.15305.x · PMID:15882166 · W2032026377
article OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This paper investigates the chemosensitivity of clear-cell ovarian cancer.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The records of all patients with clear-cell ovarian cancer (CCC) who underwent complete surgical staging and chemotherapy between 1984 and 2001 were reviewed and 39 patients identified as suitable for study. The mean patient age was 56 years, and the stage distribution was as follows: stage I, 53%; stage II, 13%; stage III, 32%; and stage IV, 2%. One in three patients with stage I disease developed recurrent disease despite adjuvant chemotherapy. Seventy percent of tumors demonstrated a response to combination carboplatin and paclitaxel. Tumors which had either a partial response or failed to respond to first-line chemotherapy demonstrated no response to second-line nonplatinum chemotherapy. Endometriosis was identified in 31% of tumors, and 18% of patients developed deep venous thrombosis (DVT); however, neither endometriosis nor DVT was associated with a poorer outcome. CCC has a high recurrence rate in early-stage disease despite adjuvant treatment with cytotoxic chemotherapy. Advanced disease does respond to carboplatin and paclitaxel, which should be the chemotherapeutic regimen of choice. New second-line agents are urgently required.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Adenocarcinoma, Clear Cell Antineoplastic Combined Chemotherapy Protocols Ovarian Neoplasms Adenocarcinoma, Clear Cell Adult Aged Antineoplastic Combined Chemotherapy Protocols Antineoplastic Combined Chemotherapy Protocols Carboplatin Carboplatin Drug Resistance, Neoplasm Endometriosis Female Humans Middle Aged Neoplasm Recurrence, Local Neoplasm Staging Ovarian Neoplasms Paclitaxel Paclitaxel

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (25)

Cited by (5)

Source provenance

europepmc
last seen: 2026-07-27T06:15:28.040536+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:15:41.664291+00:00
License: CC0 · commercial use OK